Long-term results from the CheckMate 9ER trial show that deeper tumor shrinkage is strongly linked to longer survival in patients with advanced Renal Cell Carcinoma treated with a combination of Cabozantinib (Cabometyx) and Nivolumab (Opdivo). The findings, presented in early 2026, come from a long-term follow-up of about 67 months.
Researchers found that patients who experienced the greatest tumor shrinkage had the best long-term outcomes. Those who achieved a complete response had a 4-year progression-free survival rate of about 54% and an overall survival rate of more than 84%. Patients with partial responses also showed meaningful benefits, although survival rates gradually declined as the degree of tumor shrinkage decreased.
Another notable finding was that many patients maintained their response even after stopping treatment. In several cases, responses lasted for years after therapy ended, particularly among those with the deepest responses. Side effects were common but generally manageable, with serious adverse events occurring in about 72% of responders and 67% of non-responders. Researchers say the results highlight that achieving deeper tumor responses with the cabozantinib and nivolumab combination may significantly improve long-term survival in advanced renal cell carcinoma.